Sepsis: Time to reconsider the concept

Critical Care Medicine

Volumn 36, Issue 3, 2008, Pages 964-966

  Carlet, Jean ^a   Cohen, Jonathan ^b   Calandra, Thierry ^c   Opal, Steven M ^d,e   Masur, Henry ^f  

^a SAINT JOSEPH HOSPITAL   (France)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d BROWN UNIVERSITY   (United States)

^e MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Clinical trials; Sepsis; Severe infection; Trial design

Indexed keywords

ACTIVATED PROTEIN C; AUTACOID; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL RESEARCH; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; HUMAN; INTENSIVE CARE; MEDICAL LITERATURE; MENINGITIS; METHODOLOGY; MORTALITY; PATHOPHYSIOLOGY; PERITONITIS; PRIORITY JOURNAL; SAMPLE SIZE; SEPSIS; SEPTIC SHOCK; SHORT SURVEY; CLINICAL TRIAL; FORECASTING; HOSPITALIZATION; REVIEW; STANDARD;

CLINICAL TRIALS AS TOPIC; FORECASTING; HUMANS; SEPSIS; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC;

EID: 44449166234     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0B013E318165B886     Document Type: Short Survey

References (31)

1. Eichacker PQ, Natanson C, Danner RL: Surviving sepsis: Practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 2006;355:1640-1642
2. Russell JA: Management of sepsis. N Engl J Med 2006;355:1699-1713
3. Carlet J: Prescribing indications based on successful clinical trials in sepsis: A difficult exercise. Crit Care Med 2006;34:525-529
4. Annane D, Sebille V, Carpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-871
5. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis: Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. N Engl J Med 2001;344:699-709
6. Sprung C: Corticus Study. In: Hot topic session. Meeting of the European Society of Intensive Care Medicine, Barcelona, 2006
7. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-150
8. Mira JP, Cariou A, Grall F, et al: Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 1999;282:561-568
9. Nakada TA, Hirasawa H, Oda S, et al: Influence of toll-like receptor 4, CD14, tumor necrosis factor, and interleukine-10 gene polymorphisms on clinical outcome in Japanese critically ill patients. J Surg Res 2005;129:322-328
10. Monneret G, Lepape A, Voirin N, et al: Persisting low monocyte human leucocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006;32:1175-1183
11. Cohen J, Cristofaro P, Carlet J, et al: New method of classifying infections in critically ill patients. Crit Care Med 2004;32:1510-1526
12. Bagby GJ, Plessala KJ, Wilson LA, et al: Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. J Infect Dis 1991;163:83-88
13. Cavaillon JM, Annane D: Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res 2006;12:151-170
14. Docke WD, Randow F, Syrbe U, et al: Monocyte deactivation in septic patients: Restoration by IFN-gamma treatment. Nat Med 1997;3:678-681
15. Cohen J, Guyatt G, Bernard GR, et al: New strategies for clinical trials in patients with sepsis and septic shock. Crit Care Med 2001;29:880-886 (Pubitemid 32299732)
16. Hung DT, Shakhonovich EA, Pierson E, et al: Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 2005;310:670-674
17. Jordan JA, Durso MB: Real-time polymerase chain reaction for detecting bacterial DNA directly from blood of neonates being evaluated for sepsis. J Mol Diagn 2005;7:575-581
18. Liu Y, Han JX, Huang HY, et al: Development and evaluation of 16S rDNA microarray for detecting bacterial pathogens in cerebrospinal fluid. Exp Biol Med 2005;230:587-591
19. Antonelli M, Levy M, Andrews PJD, et al: Hemodynamic monitoring in shock and implications for management. Intensive Care Med 2007;33:575-590
20. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-1596
21. Vincent JL, Sakr Y, Sprung CL, et al: Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006;34:552-554
22. Moreno RP, Metnitz PG, Almeida E, et al: SAPS 3: From evaluation of the patient to evaluation of the intensive care unit. Part 2: development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med 2005;31:1345-1355
23. Jensen JU, Heslet L, Jensen TH, et al: Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006;34:2596-2602
24. Gibot S, Cravoisy A, Levy B, et al: Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004;350:451-458
25. Ives CL, Harrison DK, Stansby GS: Tissue oxygen saturation, measured by near-infrared spectroscopy, and its relationship to surgicalsite infections. Br J Surg 2007;94:87-91
26. De Backer D, Creteur J, Preiser JC, et al: Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 2002;166:98-104
27. Van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-1367
28. Dellinger RP, Levy MM, Carlet J, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2008;36:296-327
29. Van den Berghe G, Wilmer A, Hermans G, et al: Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-461
30. Levy MM, Fink MP, Marshall JC, et al: SCCM/ESICM/ACCP/ATS/SIS 2001 International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-1256
31. Reid AA: Pneumococcal meningitis of refractory type treated by replacement of cerebrospinal fluid with penicillin. BMJ 1949;22:910